MAP4K4 and polycystic ovary syndrome: In vitro studies have shown that silencing Map4k4 (which inhibits JNK protein activation) improves the viability of GCs derived from PCOS rats, reducing apoptosis rates and influencing the expression of Bax and Bcl-2 proteins [323].